LONDON, November 11, 2013 /PRNewswire/ --
The U.S. equity market surged on Friday, November 08, 2013. The S&P 500 ended the day at 1,770.61, up 1.34%; the Dow Jones Industrial Average closed at 15,761.78, up 1.08%; and the NASDAQ Composite finished at 3,919.23, up 1.60%. Shares in the biotechnology industry surged, tracking gains in the broader market. The major movers in the industry included Medivation Inc. (NASDAQ: MDVN), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Sarepta Therapeutics Inc. (NASDAQ: SRPT) and Cell Therapeutics Inc. (NASDAQ: CTIC). AAAResearchReports.com has released full comprehensive research on MDVN, ACAD, SRPT, and CTIC. These free technical analyses can be downloaded by signing up at:
Medivation Inc.'s stock surged 3.23% on Friday, tracking gains in the broader market. The company's shares closed the day at $61.42, after fluctuating between $59.51 and $62.20 during the trading session. A total of 0.98 million shares were traded, which is below the daily average volume of 1.26 million. The company's shares have gained 9.60% in the previous three months and 19.01% in the last one month, compared to a gain of 4.68% and 3.96% in the S&P 500 during the respective periods. Moreover, Medivation Inc.'s stock is trading above its 50-day and 200-day moving averages of $58.35 and $53.47, respectively. Download free report on MDVN upon registration at:
ACADIA Pharmaceuticals Inc.'s stock closed Friday's session 4.02% higher than the previous day's closing price of $20.89. The company's shares oscillated between $20.78 and $22.26 during the trading session. A total of 2.13 million shares were traded, which is below the daily average volume of 2.57 million. The company's shares have advanced 4.67% in the previous three months, compared to the S&P 500, which has gained 4.68% during the same period. Additionally, ACADIA Pharmaceuticals Inc.'s stock is trading above its 200-day moving average of $15.93. ACAD technical report can be accessed for free by signing up at:
On Friday, Sarepta Therapeutics Inc.'s stock surged 4.08%, ending the day at $36.00 after fluctuating between $34.60 and $36.57 during the trading session. A total of 1.08 million shares were traded, which is below the daily average volume of 1.94 million. The company's shares have gained 3.03% in the previous three months, underperforming the S&P 500, which has gained 4.68% during the same period. Despite Friday's gains, Sarepta Therapeutics Inc.'s stock is trading below its 50-day and 200-day moving averages of $41.97 and $36.52, respectively. The free report on SRPT can be downloaded by signing up now at:
Shares in Cell Therapeutics Inc. rallied on Friday, tracking gains in the U.S. equity market. The company's shares fluctuated between $1.60 and $1.76 before closing the day 7.41% higher at $1.74. A total of 1.43 million shares were traded, which is below the daily average volume of 2.37 million. The company's shares have gained 58.18% in the previous three months and 0.58% in the last three trading sessions, outperforming the S&P 500, which has gained 4.68% and 0.43% during the respective periods. Moreover, Cell Therapeutics Inc.'s stock is currently trading above its 50-day and 200-day moving averages of $1.59 and $1.29, respectively. A free report on CTIC can be accessed by registering at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports